Maynard Um
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) PT Raised to $17 at Jefferies
-
-
-
-
-
-
-
RBC Capital: 'Takeout Analysis Suggests BCRX Shares Still Undervalued'
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) Reiterated at Market Outperform by Citizens: A Strong Quarter
-
-
-
-
-
-
-
Where can biotech stocks go from here? RBC answers
-
-
-
-
-
-
-
TD Cowen Resumes BioCryst Pharma (BCRX) at Buy, PT $30
-
-
-
-
-
-
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
-
-
-
-
-
-
BioCryst Pharma (BCRX): ORLADEYO Approved in Colombia
-
445,747 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

